Trialbee is collaborating with clinical research organisation (CRO) Ergomed to act as the patient recruitment platform for the latter’s newly unveiled Rare Disease Innovation Center.
The collaboration will merge Trialbee Real-World Data (RWD) with Ergomed’s new Site Advantage solution to boost recruitment of patients with rare diseases.
Furthermore, the partnership will enable improved patient centricity in developing new therapies for rare diseases and bringing them to market rapidly and with reduced costs.
The Site Advantage operating model of Ergomed is tailored to offer support to research sites and patients who are taking part in clinical research for rare diseases.
The centre will leverage Trialbee’s RWD-powered recruitment engine as well as a SaaS-based enrolment platform for the detection, recruitment and enrolment of subjects.
Furthermore, the Rare Disease Innovation Center, which offers complete trial management services for the largest pharmaceutical firms across the globe, will use Trialbee as its patient identification partner.
Ergomed will leverage the Trialbee Hive solution to enhance referrals and identify patients in an effective manner compared to standard site-based recruitment.
To boost transparency and inclusivity by tracking referrals at sites, Trialbee Honey will be utilised.
Trialbee Honey is an end-to-end approach that improves recruitment irrespective of geography or epidemiology.
Trialbee CEO Matt Walz said: “This partnership is about impacting global rare disease research in a meaningful way for our industry.
“By providing a global patient referral ecosystem with Trialbee Hive, triaged through a single onboarding platform with Trialbee Honey and fully enabled by Ergomed Site Advantage, we provide patients a frictionless journey into clinical research for rare disease, while reducing the enrolment on sites.”
In October last year, Trialbee introduced a new centralised software platform designed for recruitment teams to speed up subject recruitment timelines in trials.